Now Playing
|Videos|July 13, 2023
TALAPRO-2: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer
Toni Choueiri, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent updates from TALAPRO-2, which studied talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.
Advertisement
Advertisement
Related to this article
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
4
Dr Beck on the Practical Realities of Subcutaneous Oncology Drug Delivery
5